{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/fbrx-stock-analysis/",
 "dataUrl": "https://clearank.com/stock/fbrx-stock-analysis/data.json",
 "title": "Forte (FBRX) Stock Forecast & Price Target (2026)",
 "description": "Forte Biosciences, Inc. (FBRX) stock: Healthcare, Biotechnology. $1.6B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Forte Biosciences, Inc. (FBRX)",
 "published": "2026-07-20T09:28:34+00:00",
 "modified": "2026-09-12T19:20:59.653+00:00",
 "generated": "2026-09-13T00:42:55.031Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "FBRX",
  "name": "Forte Biosciences, Inc.",
  "type": "Common Stock",
  "exchange": "NASDAQ",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Biotechnology",
  "country": "United States",
  "website": "https://www.fortebiorx.com"
 },
 "quote": {
  "price": 76.99,
  "previousClose": 76.99,
  "change": 0,
  "changePercent": 0,
  "open": 76.99,
  "high": 76.99,
  "low": 76.99,
  "volume": 0,
  "averageVolume": 1690894,
  "marketCap": 1634427408,
  "fiftyTwoWeekHigh": 77.2,
  "fiftyTwoWeekLow": 10.11,
  "marketOpen": false,
  "asOf": "2026-09-12T19:20:59.000Z"
 },
 "statistics": {
  "pe": -16.3460717332844,
  "eps": -4.57,
  "dividendYield": 0,
  "beta": 2.645,
  "priceToSales": null,
  "priceToBook": 10.238031,
  "revenueTtm": 0,
  "grossMargin": null,
  "returnOnEquity": -0.62277
 },
 "technicals": {
  "rsi": 68.89,
  "macd": 5.3,
  "sma50": 55.12,
  "sma200": 32.86,
  "rsiSignal": "Bullish",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Hold",
  "score": 56,
  "consensus": "Hold",
  "fairValue": 76.99,
  "analystTarget": 78.91,
  "analystCount": 4,
  "wallStreetConsensus": "Hold",
  "generatedAt": "2026-09-12T19:20:59.000Z",
  "priceAtAnalysis": 76.99,
  "volatility": {
   "daily": 7.76,
   "risk": "volatile"
  }
 },
 "tradePlan": {
  "bias": "Neutral",
  "conservativeEntry": 76.22,
  "aggressiveEntry": 76.99,
  "stopLoss": 67.36,
  "stopLossPercent": 11.63,
  "targets": [
   78.51,
   80.03,
   82.32
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 34.73,
    "base": 65.92,
    "upside90th": 125.11
   },
   {
    "year": 2028,
    "downside10th": 22.8,
    "base": 56.44,
    "upside90th": 139.68
   },
   {
    "year": 2029,
    "downside10th": 15.93,
    "base": 48.32,
    "upside90th": 146.61
   },
   {
    "year": 2030,
    "downside10th": 11.48,
    "base": 41.37,
    "upside90th": 149.04
   },
   {
    "year": 2031,
    "downside10th": 8.45,
    "base": 35.42,
    "upside90th": 148.44
   },
   {
    "year": 2032,
    "downside10th": 6.31,
    "base": 30.33,
    "upside90th": 145.72
   },
   {
    "year": 2033,
    "downside10th": 4.77,
    "base": 25.97,
    "upside90th": 141.48
   },
   {
    "year": 2034,
    "downside10th": 3.63,
    "base": 22.23,
    "upside90th": 136.18
   },
   {
    "year": 2035,
    "downside10th": 2.78,
    "base": 19.03,
    "upside90th": 130.14
   },
   {
    "year": 2036,
    "downside10th": 2.15,
    "base": 16.3,
    "upside90th": 123.64
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "FBRX Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$76.99",
    "Day Range": "$76.99 to $76.99",
    "Prev Close": "$76.99",
    "52-Week Range": "$10.11 to $77.20",
    "Market Cap": "$1.63B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis"
   ]
  },
  {
   "id": "financials",
   "title": "FBRX Financial Performance",
   "text": [
    "Analysis: In the last 5 quarters, FBRX beat estimates 2 times. However, the stock fell 1 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news."
   ]
  },
  {
   "id": "analysis",
   "title": "FBRX Analysis",
   "text": [
    "Forte Biosciences (FBRX) is exhibiting bullish momentum, trading above its 50-day and 200-day moving averages ($55.12 and $32.86), and its 20-day EMA ($73.94). The Relative Strength Index (RSI) stands at a bullish 68.89, indicating strong upward price action without yet reaching overbought territory. The MACD is also positive at 5.295, further supporting the current uptrend. Key support levels are established by the 50-day and 200-day SMAs, while the current price hovers near the 20-day EMA, suggesting immediate resistance might be found around the $74 to $77 range.",
    "Insiders have made net purchases totaling $254.8K, indicating a moderate level of confidence in the company's prospects.",
    "The stock is trading above its 50-day and 200-day moving averages ($55.12 and $32.86), supported by a bullish RSI of 68.89, suggesting continued upward price pressure.",
    "Forte Biosciences has consistently reported negative EPS, with the latest quarter showing -0.97 against an estimate of -0.88, highlighting ongoing profitability challenges.",
    "The company is reporting no revenue growth, significantly lagging behind the sector average and raising concerns about its business model's viability.",
    "The base case scenario for Forte Biosciences (FBRX) over the next 6-12 months suggests continued trading around its current levels, given its median analyst target price of $77.00 aligns with the current stock price. The bullish technical momentum, with the stock trading above key moving averages and a strong RSI, may provide some support for near-term price stability. However, the fundamental challenges of negative EPS and zero revenue growth present a significant overhang, limiting the potential for substantial upside without a clear catalyst for growth or profitability. The thesis could be altered by a breakthrough in the company's drug development pipeline, leading to positive clinical trial results and future revenue streams, which would likely trigger a re-rating by analysts and investors. Conversely, continued operational losses without a clear path to revenue generation could lead to a downward revision of price targets and increased selling pressure, especially if the company requires further capital raises. The negative forward-looking growth estimates also pose a substantial risk to any bullish outlook."
   ],
   "lists": {
    "ProTips": [
     "Insiders have been net buyers of Forte Biosciences (FBRX) stock, investing $254.8K in recent transactions, which may signal underlying confidence in the company's future prospects.",
     "The stock is trading above its 50-day and 200-day moving averages ($55.12 and $32.86), indicating positive short-term and medium-term technical trends, but investors should monitor for any potential pullbacks towards these support levels.",
     "Given the company's negative EPS and zero revenue growth, investors should closely watch for any news regarding pipeline advancements or strategic shifts that could fundamentally alter its growth trajectory."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Insider Buying Activity",
     "text": "Insiders have made net purchases totaling $254.8K, indicating a moderate level of confidence in the company's prospects.",
     "source": "Insider Transactions"
    },
    {
     "type": "Bullish",
     "title": "Positive Technical Momentum",
     "text": "The stock is trading above its 50-day and 200-day moving averages ($55.12 and $32.86), supported by a bullish RSI of 68.89, suggesting continued upward price pressure.",
     "source": "Technical Analysis"
    },
    {
     "type": "Bearish",
     "title": "Persistent Negative EPS",
     "text": "Forte Biosciences has consistently reported negative EPS, with the latest quarter showing -0.97 against an estimate of -0.88, highlighting ongoing profitability challenges.",
     "source": "Earnings Reports"
    },
    {
     "type": "Bearish",
     "title": "Zero Revenue Growth",
     "text": "The company is reporting no revenue growth, significantly lagging behind the sector average and raising concerns about its business model's viability.",
     "source": "Financial Data"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Forte Biosciences (FBRX) presents a valuation paradox, with a negative EPS of -4.57 rendering its P/E ratio of -16.35 (negative due to EPS of $-4.57). The company reports zero revenue growth, a stark contrast to the Healthcare sector's median revenue growth of 8.1%, raising concerns about its ability to generate sales. While the stock is trading at its median analyst target price of $77.00, offering no immediate upside, the lack of revenue and persistent losses suggest a premium valuation based on future potential rather than current performance. The company's balance sheet strength is not detailed, but the negative EPS and zero revenue growth indicate significant operational challenges. The forward-looking growth estimates are also concerning, with a projected -11.6% CAGR over the next five years, suggesting a potential contraction in business scale. This fundamental picture, characterized by losses and stagnant revenue, warrants caution despite the positive technical indicators.",
    "Forte Biosciences (FBRX) most recently reported an EPS of -0.97 for the quarter ending August 12, 2026, missing the analyst estimate of -0.88 by 10.23%. This follows a pattern of consistent EPS misses, including -1.24 against -1.16 in May 2026 and -1.45 against -1.15 in March 2026. While the company did show a positive surprise of 7.48% in November 2025, the overall trend indicates a struggle to meet earnings expectations.",
    "Forte Biosciences (FBRX) faces significant risks stemming from its persistent negative EPS and complete lack of revenue growth, which are not aligned with the broader Healthcare sector's performance. The company's forward-looking growth estimates are also negative, suggesting a potential long-term contraction. Also, the stock is trading precisely at its median analyst target price, offering no immediate upside and highlighting the market's current equilibrium between technical strength and fundamental weakness."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "1.63B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "N/A (Negative EPS)"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "-4.57"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "77.20"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "10.11"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bullish RSI Bullish SMA Cross Bullish Price vs SMA Bullish MACD Bullish Golden Cross in effect with the 50-day SMA ($55.12) above the 200-day SMA ($32.86), price action is firmly bullish above key moving averages."
   ],
   "facts": {
    "RSI": "Bullish",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "68.89"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "5.30"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "55.12"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "32.86"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.10",
    "Correlation with Nasdaq 100 (QQQ)": "+0.08",
    "Correlation with Bitcoin (BTC)": "+0.14",
    "Correlation with Gold (XAU)": "+0.01"
   }
  },
  {
   "id": "trade-plans",
   "title": "FBRX Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Enter now if confident",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (68.9) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$78.51",
    "TARGET 2": "$80.03",
    "TARGET 3": "$82.32",
    "STOP LOSS": "$67.36"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "⚠️ Limited data: Based on ~1 year of trading history. Patterns may not be statistically significant."
   ],
   "facts": {
    "Average Jan return": "-3.38%",
    "Average Feb return": "+10.11%",
    "Average Mar return": "-2.07%",
    "Average Apr return": "+0.81%",
    "Average May return": "-5.75%",
    "Average Jun return": "+4.70%",
    "Average Jul return": "+20.56%",
    "Average Aug return": "+1.76%",
    "Average Sep return": "-11.73%",
    "Average Oct return": "-12.42%",
    "Average Nov return": "+52.20%",
    "Average Dec return": "+3.71%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "7.76%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in FBRX in April 2017 would be worth about $165 today, compared with about $33,089 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in FBRX today could grow to about $2,117 by 2036 in the base case, with a bull case near $16,059 and a bear case around $279. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "FBRX Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $41.37 for FBRX by 2030 in the base case, from $76.99 today (0.5x over 4 years). The downside path ends near $11.48. These are outcomes of a Monte Carlo simulation run on FBRX's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using FBRX's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "FBRX simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$34.73",
        "$65.92",
        "$125"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$22.80",
        "$56.44",
        "$140"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$15.93",
        "$48.32",
        "$147"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$11.48",
        "$41.37",
        "$149"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$8.45",
        "$35.42",
        "$148"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$6.31",
        "$30.33",
        "$146"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$4.77",
        "$25.97",
        "$141"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$3.63",
        "$22.23",
        "$136"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$2.78",
        "$19.03",
        "$130"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$2.15",
        "$16.30",
        "$124"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "NEOG Neogen Corp. NASDAQ $11.78 +0.08%",
     "url": "https://clearank.com/stock/neogen-neog/"
    },
    {
     "text": "VEEV Veeva Systems Inc. NYSE $262.40 +0.54%",
     "url": "https://clearank.com/stock/veev-stock-analysis/"
    },
    {
     "text": "CI The Cigna Group NYSE $280.76 -0.05%",
     "url": "https://clearank.com/stock/cigna-group-ci/"
    },
    {
     "text": "WST West Pharmaceutical Services Inc. NYSE $346.23 +0.58%",
     "url": "https://clearank.com/stock/wst-stock-analysis/"
    },
    {
     "text": "HCA HCA Healthcare, Inc. NYSE $426.94 +1.36%",
     "url": "https://clearank.com/stock/hca-healthcare-hca/"
    },
    {
     "text": "IONS Ionis Pharmaceuticals, Inc. NASDAQ $54.21 -2.59%",
     "url": "https://clearank.com/stock/ions-stock-analysis/"
    },
    {
     "text": "BIIB Biogen Inc. NASDAQ $217.10 +0.78%",
     "url": "https://clearank.com/stock/biib-stock-analysis/"
    },
    {
     "text": "EW Edwards Lifesciences Corporation NYSE $84.37 -2.77%",
     "url": "https://clearank.com/stock/ew-stock-analysis/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "DIA vs SPY Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/dia-vs-spy/"
    },
    {
     "text": "VOO vs IVV Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/voo-vs-ivv/"
    },
    {
     "text": "CSX vs NSC Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/csx-vs-nsc/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "FBRX Insider Trading Analysis",
   "facts": {
    "Bought": "$254.8K",
    "Sold": "None",
    "Insiders": "2",
    "Avg Transaction": "$254.8K"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in FBRX",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Jul 1, 2026",
       "cells": [
        "RILEY ANTONY A Chief Financial Officer",
        "Grant",
        "375",
        "-"
       ]
      },
      {
       "label": "Jul 1, 2026",
       "cells": [
        "WAGNER PAUL A Chief Executive Officer",
        "Grant",
        "1.3K",
        "-"
       ]
      },
      {
       "label": "Apr 1, 2026",
       "cells": [
        "RILEY ANTONY A Chief Financial Officer",
        "Grant",
        "375",
        "-"
       ]
      },
      {
       "label": "Apr 1, 2026",
       "cells": [
        "WAGNER PAUL A Chief Executive Officer",
        "Grant",
        "1.3K",
        "-"
       ]
      },
      {
       "label": "Dec 31, 2025",
       "cells": [
        "RILEY ANTONY A Chief Financial Officer",
        "Grant",
        "375",
        "-"
       ]
      },
      {
       "label": "Dec 31, 2025",
       "cells": [
        "WAGNER PAUL A Chief Executive Officer",
        "Grant",
        "1.3K",
        "-"
       ]
      },
      {
       "label": "Dec 30, 2025",
       "cells": [
        "RILEY ANTONY A Chief Financial Officer",
        "Buy",
        "9.7K",
        "$254.8K"
       ]
      },
      {
       "label": "Oct 1, 2025",
       "cells": [
        "RILEY ANTONY A Chief Financial Officer",
        "Grant",
        "375",
        "-"
       ]
      },
      {
       "label": "Oct 1, 2025",
       "cells": [
        "WAGNER PAUL A Chief Executive Officer",
        "Grant",
        "1.3K",
        "-"
       ]
      },
      {
       "label": "Jul 1, 2025",
       "cells": [
        "RILEY ANTONY A Chief Financial Officer",
        "Grant",
        "375",
        "-"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Forte+Biosciences%2C+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "Is Forte Biosciences (FBRX) stock a buy right now?",
   "answer": "Forte Biosciences (FBRX) is currently rated a 'Hold' with a consensus score of 56. The stock is trading at $76.99, which is exactly at its median analyst target price of $77.00, offering no immediate upside. While insiders have been net buyers, the company faces significant fundamental challenges including negative EPS and zero revenue growth."
  },
  {
   "question": "What is Forte Biosciences' (FBRX) price forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, Forte Biosciences' (FBRX) stock price is projected to be $41.37 in 2030 under a base case scenario, with a downside projection of $11.48 and an upside projection of $149.04. These are statistical outcomes and not guaranteed price targets."
  },
  {
   "question": "What are the biggest risks facing Forte Biosciences (FBRX)?",
   "answer": "The primary risks for Forte Biosciences (FBRX) include its persistent negative earnings per share, a complete absence of revenue growth, and negative forward-looking growth estimates. The stock is also trading at its median analyst target price, limiting immediate upside potential."
  },
  {
   "question": "How is Forte Biosciences (FBRX) performing technically?",
   "answer": "Technically, Forte Biosciences (FBRX) shows bullish momentum, trading above its 50-day and 200-day moving averages ($55.12 and $32.86) with a bullish RSI at 68.9. The stock is currently trading near its 20-day EMA, indicating positive short-term price action."
  },
  {
   "question": "What is Forte Biosciences' (FBRX) consensus rating?",
   "answer": "The consensus rating for Forte Biosciences (FBRX) is 'Hold', supported by a consensus score of 56 out of 100. This reflects a mixed view among the four Wall Street analysts covering the stock."
  },
  {
   "question": "Are there any recent earnings surprises for Forte Biosciences (FBRX)?",
   "answer": "Forte Biosciences (FBRX) has recently missed earnings expectations, reporting an EPS of -0.97 against an estimate of -0.88 for the quarter ending August 12, 2026. This follows a pattern of earnings misses in previous quarters."
  },
  {
   "question": "What is the revenue growth outlook for Forte Biosciences (FBRX)?",
   "answer": "Forte Biosciences (FBRX) currently reports zero revenue growth, which is significantly below the Healthcare sector median of 8.1%. Forward-looking revenue estimates also show no growth for the current and next quarters, and a negative compound annual growth rate of -11.6% is projected over the next five years."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "NEOG",
    "name": "Neogen Corp. NASDAQ",
    "price": "$11.78",
    "change": "+0.08%",
    "url": "https://clearank.com/stock/neogen-neog/"
   },
   {
    "ticker": "VEEV",
    "name": "Veeva Systems Inc. NYSE",
    "price": "$262.40",
    "change": "+0.54%",
    "url": "https://clearank.com/stock/veev-stock-analysis/"
   },
   {
    "ticker": "CI",
    "name": "The Cigna Group NYSE",
    "price": "$280.76",
    "change": "-0.05%",
    "url": "https://clearank.com/stock/cigna-group-ci/"
   },
   {
    "ticker": "WST",
    "name": "West Pharmaceutical Services Inc. NYSE",
    "price": "$346.23",
    "change": "+0.58%",
    "url": "https://clearank.com/stock/wst-stock-analysis/"
   },
   {
    "ticker": "HCA",
    "name": "HCA Healthcare, Inc. NYSE",
    "price": "$426.94",
    "change": "+1.36%",
    "url": "https://clearank.com/stock/hca-healthcare-hca/"
   },
   {
    "ticker": "IONS",
    "name": "Ionis Pharmaceuticals, Inc. NASDAQ",
    "price": "$54.21",
    "change": "-2.59%",
    "url": "https://clearank.com/stock/ions-stock-analysis/"
   },
   {
    "ticker": "BIIB",
    "name": "Biogen Inc. NASDAQ",
    "price": "$217.10",
    "change": "+0.78%",
    "url": "https://clearank.com/stock/biib-stock-analysis/"
   },
   {
    "ticker": "EW",
    "name": "Edwards Lifesciences Corporation NYSE",
    "price": "$84.37",
    "change": "-2.77%",
    "url": "https://clearank.com/stock/ew-stock-analysis/"
   }
  ],
  "comparisons": [
   {
    "ticker": "DIA vs SPY Comparison",
    "name": "",
    "url": "https://clearank.com/compare/dia-vs-spy/"
   },
   {
    "ticker": "VOO vs IVV Comparison",
    "name": "",
    "url": "https://clearank.com/compare/voo-vs-ivv/"
   },
   {
    "ticker": "CSX vs NSC Comparison",
    "name": "",
    "url": "https://clearank.com/compare/csx-vs-nsc/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "KEYS",
    "text": "Keysight Technologies, Inc.",
    "url": "https://clearank.com/stock/keys-stock-analysis/"
   },
   {
    "ticker": "BRO",
    "text": "Brown & Brown Inc.",
    "url": "https://clearank.com/stock/bro-stock-analysis/"
   },
   {
    "ticker": "SYY",
    "text": "Sysco Corp.",
    "url": "https://clearank.com/stock/syy-stock-analysis/"
   },
   {
    "ticker": "FIS",
    "text": "Fidelity National Information Services, Inc.",
    "url": "https://clearank.com/stock/fis-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "XHLD",
    "text": "↑ 15.59%",
    "url": "https://clearank.com/stock/xhld-stock-analysis/"
   },
   {
    "ticker": "HPE",
    "text": "↑ 12.44%",
    "url": "https://clearank.com/stock/hewlett-packard-enterprise-hpe/"
   },
   {
    "ticker": "DELL",
    "text": "↑ 11.98%",
    "url": "https://clearank.com/stock/dell-technologies-dell/"
   },
   {
    "ticker": "NEAR/USD",
    "text": "↓ 10.99%",
    "url": "https://clearank.com/crypto/near-protocol-near-usd/"
   },
   {
    "ticker": "IMSR",
    "text": "↓ 9.79%",
    "url": "https://clearank.com/stock/terrestrial-energy-imsr/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "BNTX",
    "text": "BioNTech SE",
    "url": "https://clearank.com/stock/bntx-stock-analysis/"
   },
   {
    "ticker": "CAPR",
    "text": "Capricor Therapeutics, Inc.",
    "url": "https://clearank.com/stock/capr-stock-analysis/"
   },
   {
    "ticker": "CRNX",
    "text": "Crinetics Pharmaceuticals",
    "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/"
   },
   {
    "ticker": "CRSP",
    "text": "CRISPR Therapeutics AG",
    "url": "https://clearank.com/stock/crispr-therapeutics-crsp/"
   },
   {
    "ticker": "IONS",
    "text": "Ionis",
    "url": "https://clearank.com/stock/ions-stock-analysis/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "url": "https://clearank.com",
     "sameAs": [
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "email": "info@clearank.com",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "description": "The CleaRank vision is to bring clarity to the online trading industry and protect trader interests. We use our proprietary technology, expert analysis and verified trader insights, to deliver data driven broker evaluations you can trust. Our CLEAR™ Score is our foundation, a transparent, unbiased methodology that assesses brokers and firms based on the most critical factors including regulation, fees, platform reliability, and real user experiences. We are here to change an unfair system and unlike other review sites that are influenced by partnerships or subjective opinions, CleaRank is 100% independent–abiding by our rigorous CLEAR™ editorial code. We do not accept financial incentives from brokers, so what you see is what you get with no hidden agendas, just honest, actionable feedback. Clear data. Honest reviews. That's the CleaRank promise",
     "numberOfEmployees": {
      "@type": "QuantitativeValue",
      "value": "40"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/07/fbrx-forte-biosciences-analysis-2026-07.png",
     "url": "https://clearank.com/wp-content/uploads/2026/07/fbrx-forte-biosciences-analysis-2026-07.png",
     "width": "1280",
     "height": "720",
     "caption": "Forte Biosciences (FBRX) stock price analysis chart for July 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/fbrx-stock-analysis/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/fbrx-stock-analysis/",
        "name": "Forte (FBRX) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/fbrx-stock-analysis/#webpage",
     "url": "https://clearank.com/stock/fbrx-stock-analysis/",
     "name": "Forte (FBRX) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-20T09:28:34+00:00",
     "dateModified": "2026-09-12T19:20:59+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/fbrx-forte-biosciences-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/fbrx-stock-analysis/#breadcrumb"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/writer/clearank/",
     "name": "CleaRank",
     "description": "CleaRank's vision is to bring clarity to the online trading industry and protecting trader interests by delivering data-driven broker evaluations you can trust.",
     "url": "https://clearank.com/writer/clearank/",
     "image": {
      "@type": "ImageObject",
      "@id": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "url": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "caption": "CleaRank",
      "inLanguage": "en-US"
     },
     "sameAs": [
      "https://clearank.com/",
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     },
     "logo": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg"
    },
    {
     "@type": "Article",
     "headline": "Forte (FBRX) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-20T09:28:34+00:00",
     "dateModified": "2026-09-12T19:20:59+00:00",
     "author": {
      "@id": "https://clearank.com/writer/clearank/",
      "name": "CleaRank"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "description": "Forte Biosciences, Inc. (FBRX) stock: Healthcare, Biotechnology. $1.6B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "name": "Forte (FBRX) Stock Forecast & Price Target (2026)",
     "@id": "https://clearank.com/stock/fbrx-stock-analysis/#richSnippet",
     "isPartOf": {
      "@id": "https://clearank.com/stock/fbrx-stock-analysis/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/fbrx-forte-biosciences-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/fbrx-stock-analysis/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FinancialProduct",
   "name": "Forte Biosciences, Inc. (FBRX)",
   "tickerSymbol": "FBRX",
   "url": "https://clearank.com/stock/fbrx-stock-analysis/",
   "description": "AI-powered financial analysis for Forte Biosciences, Inc. (FBRX) including technical indicators, market metrics, valuation, and price targets - refreshed daily by CleaRank Financial AI.",
   "exchange": "NASDAQ",
   "offers": {
    "@type": "Offer",
    "price": 76.99,
    "priceCurrency": "USD",
    "availability": "https://schema.org/InStock",
    "url": "https://clearank.com/stock/fbrx-stock-analysis/",
    "priceValidUntil": "2026-09-14"
   }
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "Is Forte Biosciences (FBRX) stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Forte Biosciences (FBRX) is currently rated a 'Hold' with a consensus score of 56. The stock is trading at $76.99, which is exactly at its median analyst target price of $77.00, offering no immediate upside. While insiders have been net buyers, the company faces significant fundamental challenges including negative EPS and zero revenue growth."
     }
    },
    {
     "@type": "Question",
     "name": "What is Forte Biosciences' (FBRX) price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, Forte Biosciences' (FBRX) stock price is projected to be $41.37 in 2030 under a base case scenario, with a downside projection of $11.48 and an upside projection of $149.04. These are statistical outcomes and not guaranteed price targets."
     }
    },
    {
     "@type": "Question",
     "name": "What are the biggest risks facing Forte Biosciences (FBRX)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The primary risks for Forte Biosciences (FBRX) include its persistent negative earnings per share, a complete absence of revenue growth, and negative forward-looking growth estimates. The stock is also trading at its median analyst target price, limiting immediate upside potential."
     }
    },
    {
     "@type": "Question",
     "name": "How is Forte Biosciences (FBRX) performing technically?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Technically, Forte Biosciences (FBRX) shows bullish momentum, trading above its 50-day and 200-day moving averages with a bullish RSI of 68.89. The stock is currently trading near its 20-day EMA, indicating positive short-term price action."
     }
    },
    {
     "@type": "Question",
     "name": "What is Forte Biosciences' (FBRX) consensus rating?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The consensus rating for Forte Biosciences (FBRX) is 'Hold', supported by a consensus score of 56 out of 100. This reflects a mixed view among the four Wall Street analysts covering the stock."
     }
    },
    {
     "@type": "Question",
     "name": "Are there any recent earnings surprises for Forte Biosciences (FBRX)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Forte Biosciences (FBRX) has recently missed earnings expectations, reporting an EPS of -0.97 against an estimate of -0.88 for the quarter ending August 12, 2026. This follows a pattern of earnings misses in previous quarters."
     }
    },
    {
     "@type": "Question",
     "name": "What is the revenue growth outlook for Forte Biosciences (FBRX)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Forte Biosciences (FBRX) currently reports zero revenue growth, which is significantly below the Healthcare sector median of 8.1%. Forward-looking revenue estimates also show no growth for the current and next quarters, and a negative compound annual growth rate of -11.6% is projected over the next five years."
     }
    }
   ]
  }
 ]
}